查看购物车
  • Traditional Chinese
  • English
2021-2031年亚太地区治疗性疫苗市场报告：范围、细分、动态和竞争分析
市场调查报告书
商品编码
1871435

2021-2031年亚太地区治疗性疫苗市场报告：范围、细分、动态和竞争分析

Asia Pacific Therapeutic Vaccines Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 126 Pages | 订单完成后即时交付

价格

预计亚太地区治疗性疫苗市场将显着成长，到 2031 年将达到约 8,586.288 万美元，高于 2024 年的 3421.387 万美元，2024 年至 2031 年的年复合成长率(CAGR) 预计为 14.0%。

执行摘要和市场分析

亚太地区的治疗性疫苗市场正经历强劲成长，主要得益于技术进步和疫苗研发投入的增加。中国和印度是这一增长的主要推动力，两国人口众多，免疫接种计划覆盖面广，医疗保健支出不断增长。日本先进的医疗保健体系和高疫苗接种率也显着促进了市场扩张。此外，澳洲正透过政府的大力支持和提高大众对疫苗益处的认识，不断提升其市场份额。

儘管市场呈现成长态势，但仍面临许多挑战，例如严格的监管架构、高昂的生产和研发成本，以及病患和医疗专业人员认知度有限。应对这些挑战对于亚太地区治疗性疫苗产业的持续发展至关重要。

市场区隔分析

治疗性疫苗市场可依产品类型、技术和最终用户进行细分：

  • 按产品划分：市场分为癌症疫苗、传染病疫苗和其他疫苗，其中癌症疫苗在 2024 年将占据最大的市场份额。
  • 按技术划分：市场分为同种异体疫苗和自体疫苗，到 2024 年，同种异体疫苗将占据市场份额的领先地位。
  • 按最终用户划分：最终用户包括医院、诊所等，其中医院在 2024 年将占最大份额。

市场展望

对创新治疗方案的需求正推动治疗性疫苗领域的大量投资和发展。越来越多的候选疫苗正处于不同的研发阶段，这就是这一趋势的体现。生物技术领域的创新研发正在催生针对多种疾病的先进治疗性疫苗，包括癌症等慢性疾病和新型感染。例如，Moderna公司的mRNA-4157目前正处于第二期临床试验阶段，与免疫检查点抑制剂联合用于治疗黑色素瘤显示出良好的前景。治疗性疫苗研发管线也不断扩展，以应对自体免疫疾病和传染病，例如HIV、HPV和HBV。

多家公司正致力于提昇科学技术水平，以研发和推出新型治疗性疫苗。针对多种疾病的候选疫苗研发管线不断扩展，为满足尚未满足的医疗需求提供了重要机会。以下是值得关注的治疗性疫苗候选产品概要：

  • ADXS11-001：一种处于 I/II 期临床试验的子宫颈癌细菌载体疫苗。
  • ISA101：一种用于治疗实体瘤的胜肽/蛋白质疫苗，目前处于 II 期临床试验阶段。
  • NeoVax：一种用于治疗肾癌的个人化胜肽疫苗，目前处于 I 期临床试验阶段。
  • mRNA-4157：一种基于mRNA的新抗原疫苗，目前处于黑色素瘤I/II期临床试验阶段。
  • VGX-3100：一种用于治疗子宫颈癌和头颈癌的DNA疫苗，目前处于I/II期临床试验阶段。
  • NASVAC：一种用于治疗B型肝炎病毒感染的病毒样颗粒疫苗，目前处于 III 期临床试验阶段。
  • iHIVARNA：一种处于 I 期临床试验阶段的 HIV 感染 mRNA 疫苗。

正在进行的临床试验表明，治疗性疫苗市场前景光明，新的治疗方案不断涌现，以满足尚未满足的医疗需求。

国家概况

亚太地区治疗性疫苗市场涵盖中国、日本、印度、澳洲、韩国等国。预计到2024年，澳洲将保持最大的市场份额，这主要得益于其强大的医疗基础设施和在疫苗研发领域的积极参与。值得注意的是，澳洲研究人员在研发EB病毒（Epstein-Barr virus，EBV）治疗性疫苗方面取得了显着进展，该疫苗有望彻底改变EB病毒相关疾病（包括多发性硬化症和某些癌症）的治疗方式。

此外，南澳大利亚州正凭藉其先进的mRNA生产设施BioCina，确立其在mRNA技术领域的领先地位。该设施旨在提高治疗药物和疫苗的产量，并获得了澳洲政府1000万美元的资金支持。

公司简介

治疗性疫苗市场的主要参与者包括CureVac SE、THERAVECTYS SA、Transgene SA、INOVIO Pharmaceuticals Inc、ISA Pharmaceuticals BV、Amgen Inc、Merck & Co Inc、印度血清研究所、BioNTech SE和Dendreon。这些公司正采取多种策略，包括扩张、产品创新以及併购，以增强市场份额并提供创新产品。

目录

第一章：引言

第二章：执行概要

  • 关键见解

第三章：研究方法

  • 二手研究
  • 初步研究
    • 假设的提出：
    • 宏观经济因素分析：
    • 发展基数：
    • 数据三角测量：
    • 国家层面资料：

第四章：亚太地区治疗性疫苗市场－主要市场动态

  • 市场驱动因素
    • 慢性病盛行率上升
    • 增加疫苗研发的投资与资金投入
  • 市场限制
    • 监管挑战
  • 市场机会
    • 拓展产品线
  • 未来趋势
    • 疫苗技术的进步
  • 驾驶员和安全带的影响：

第五章：治疗性疫苗市场－亚太市场分析

  • 2021-2031年亚太地区治疗性疫苗市场收入
  • 亚太地区治疗性疫苗市场预测分析

第六章：亚太地区治疗性疫苗市场分析－依产品分类

  • 癌症疫苗
  • 传染病疫苗
  • 其他的

第七章：亚太地区治疗性疫苗市场分析－依技术划分

  • 同种异体疫苗
  • 自体疫苗

第八章：亚太地区治疗性疫苗市场分析－依最终用户划分

  • 医院
  • 诊所
  • 其他的

第九章：亚太地区治疗性疫苗市场—国家分析

  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 亚太其他地区

第十章：治疗性疫苗市场－产业概况

  • 概述
  • 治疗性疫苗市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第十一章：公司简介

  • Dendreon
  • BioNTech SE
  • Serum Institute of India Pvt. Ltd
  • Merck & Co Inc
  • Amgen Inc
  • ISA Pharmaceuticals BV
  • INOVIO Pharmaceuticals Inc
  • Transgene SA
  • THERAVECTYS SA
  • CureVac SE

第十二章：附录

Product Code: BMIRE00032092

The Asia Pacific therapeutic vaccines market is projected to grow significantly, reaching approximately US$ 85,862.88 thousand by 2031, up from US$ 34,213.87 thousand in 2024, with an estimated compound annual growth rate (CAGR) of 14.0% from 2024 to 2031.

Executive Summary and Market Analysis

The therapeutic vaccine market in the Asia Pacific region is witnessing robust growth, primarily fueled by advancements in technology and increased funding for vaccine research. Key players in this growth include China and India, which benefit from large populations, extensive immunization programs, and rising healthcare expenditures. Japan's advanced healthcare system and high vaccination rates also contribute significantly to market expansion. Furthermore, Australia is enhancing its market presence through strong government support and heightened public awareness regarding vaccination benefits.

Despite this growth, the market faces challenges such as stringent regulatory frameworks, high production and development costs, and limited awareness among patients and healthcare professionals. Addressing these challenges is crucial for the continued growth of the therapeutic vaccine sector in the Asia Pacific.

Market Segmentation Analysis

The therapeutic vaccines market can be segmented by product type, technology, and end user:

  • By Product: The market is divided into cancer vaccines, infectious disease vaccines, and others, with cancer vaccines holding the largest market share in 2024.
  • By Technology: The market is categorized into allogenic and autologous vaccines, with allogenic vaccines leading in market share in 2024.
  • By End User: The end users include hospitals, clinics, and others, with hospitals accounting for the largest share in 2024.

Market Outlook

The demand for innovative treatment options is driving significant investments and advancements in the therapeutic vaccines sector. The increasing number of clinical candidates progressing through various development stages is indicative of this trend. Innovative research and development in biotechnology are producing advanced therapeutic vaccines targeting a range of diseases, including chronic conditions like cancer and newer infections. For instance, Moderna's mRNA-4157 is currently in phase 2 trials, showing promise in combination with checkpoint inhibitors for melanoma treatment. The therapeutic vaccine pipeline is also expanding to address autoimmune diseases and infectious diseases such as HIV, HPV, and HBV.

Several companies are focusing on scientific and technical excellence to develop and launch new therapeutic vaccines. The expanding pipeline of vaccine candidates targeting diverse diseases presents significant opportunities to meet unmet medical needs. Below is a summary of notable therapeutic vaccine candidates:

  • ADXS11-001: A bacterial vector vaccine in Phase I/II for cervical carcinoma.
  • ISA101: A peptide/protein vaccine in Phase II for solid tumors.
  • NeoVax: A personalized peptide vaccine in Phase I for kidney cancer.
  • mRNA-4157: An mRNA-based neoantigen vaccine in Phase I/II for melanoma.
  • VGX-3100: A DNA vaccine in Phase I/II for cervical and head and neck cancers.
  • NASVAC: A virus-like particle vaccine in Phase III for HBV infection.
  • iHIVARNA: An mRNA vaccine in Phase I for HIV infection.

The ongoing clinical trials indicate a promising future for the therapeutic vaccines market, with new treatment options emerging to address unmet medical needs.

Country Insights

The Asia Pacific therapeutic vaccines market includes countries such as China, Japan, India, Australia, South Korea, and others. Australia is expected to maintain the largest market share in 2024, driven by its strong healthcare infrastructure and active involvement in vaccine development. Notably, Australian researchers have made significant progress in developing a therapeutic vaccine for Epstein-Barr virus (EBV), which could revolutionize treatment for diseases associated with EBV, including multiple sclerosis and certain cancers.

Additionally, South Australia is establishing itself as a leader in mRNA technology with the development of a state-of-the-art mRNA production facility, BioCina. This facility aims to enhance the production of therapeutic drugs and vaccines, supported by US$ 10 million in funding from the Australian government.

Company Profiles

Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative products.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. Asia Pacific Therapeutic Vaccines Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Prevalence of Chronic Conditions
    • 4.1.2 Increasing Investments and Funding for Vaccine Development
  • 4.2 Market Restraints
    • 4.2.1 Regulatory Challenges
  • 4.3 Market Opportunities
    • 4.3.1 Extending Product Pipeline
  • 4.4 Future Trends
    • 4.4.1 Advancements in Vaccine Technology
  • 4.5 Impact of Drivers and Restraints:

5. Therapeutic Vaccines Market - Asia Pacific Market Analysis

  • 5.1 Asia Pacific Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • 5.2 Asia Pacific Therapeutic Vaccines Market Forecast Analysis

6. Asia Pacific Therapeutic Vaccines Market Analysis - by Product

  • 6.1 Cancer Vaccine
    • 6.1.1 Overview
    • 6.1.2 Cancer Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 6.2 infectious Disease Vaccine
    • 6.2.1 Overview
    • 6.2.2 infectious Disease Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 6.3 Others
    • 6.3.1 Overview
    • 6.3.2 Others: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

7. Asia Pacific Therapeutic Vaccines Market Analysis - by Technology

  • 7.1 Allogenic Vaccine
    • 7.1.1 Overview
    • 7.1.2 Allogenic Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 7.2 Autologous Vaccine
    • 7.2.1 Overview
    • 7.2.2 Autologous Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

8. Asia Pacific Therapeutic Vaccines Market Analysis - by End User

  • 8.1 Hospitals
    • 8.1.1 Overview
    • 8.1.2 Hospitals: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 8.2 Clinics
    • 8.2.1 Overview
    • 8.2.2 Clinics: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

9. Asia Pacific Therapeutic Vaccines Market - Country Analysis

  • 9.1 Asia Pacific
    • 9.1.1 Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.1 Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.2 China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.2.1 China: Asia Pacific Therapeutic Vaccines Market Share - by Product
        • 9.1.1.2.2 China: Asia Pacific Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.2.3 China: Asia Pacific Therapeutic Vaccines Market Share - by End User
      • 9.1.1.3 Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.3.1 Japan: Asia Pacific Therapeutic Vaccines Market Share - by Product
        • 9.1.1.3.2 Japan: Asia Pacific Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.3.3 Japan: Asia Pacific Therapeutic Vaccines Market Share - by End User
      • 9.1.1.4 India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.4.1 India: Asia Pacific Therapeutic Vaccines Market Share - by Product
        • 9.1.1.4.2 India: Asia Pacific Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.4.3 India: Asia Pacific Therapeutic Vaccines Market Share - by End User
      • 9.1.1.5 South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.5.1 South Korea: Asia Pacific Therapeutic Vaccines Market Share - by Product
        • 9.1.1.5.2 South Korea: Asia Pacific Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.5.3 South Korea: Asia Pacific Therapeutic Vaccines Market Share - by End User
      • 9.1.1.6 Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.6.1 Australia: Asia Pacific Therapeutic Vaccines Market Share - by Product
        • 9.1.1.6.2 Australia: Asia Pacific Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.6.3 Australia: Asia Pacific Therapeutic Vaccines Market Share - by End User
      • 9.1.1.7 Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.7.1 Rest of APAC: Asia Pacific Therapeutic Vaccines Market Share - by Product
        • 9.1.1.7.2 Rest of APAC: Asia Pacific Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.7.3 Rest of APAC: Asia Pacific Therapeutic Vaccines Market Share - by End User

10. Therapeutic Vaccines Market - Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in the Therapeutic Vaccines Market
  • 10.3 Organic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Inorganic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Dendreon
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 BioNTech SE
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Serum Institute of India Pvt. Ltd
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Merck & Co Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Amgen Inc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 ISA Pharmaceuticals BV
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 INOVIO Pharmaceuticals Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Transgene SA
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 THERAVECTYS SA
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 CureVac SE
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. Asia Pacific Therapeutic Vaccines Market Segmentation
  • Table 2. Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Table 3. Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Product
  • Table 4. Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Technology
  • Table 5. Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by End User
  • Table 6. Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Country
  • Table 7. China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 8. China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 9. China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 10. Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 11. Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 12. Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 13. India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 14. India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 15. India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 16. South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 17. South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 18. South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 19. Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 20. Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 21. Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 22. Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 23. Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 24. Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 25. Recent Organic Growth Strategies in the Therapeutic Vaccines Market
  • Table 26. Recent Inorganic Growth Strategies in the Therapeutic Vaccines Market
  • Table 27. Glossary of Terms, Therapeutic Vaccines Market

List Of Figures

  • Figure 1. Asia Pacific Therapeutic Vaccines Market Segmentation - Country
  • Figure 2. Asia Pacific Therapeutic Vaccines Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Asia Pacific Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • Figure 5. Asia Pacific Therapeutic Vaccines Market Share (%) - by Product (2024 and 2031)
  • Figure 6. Cancer Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 7. infectious Disease Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 8. Others: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 9. Asia Pacific Therapeutic Vaccines Market Share (%) - by Technology (2024 and 2031)
  • Figure 10. Allogenic Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 11. Autologous Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 12. Asia Pacific Therapeutic Vaccines Market Share (%) - by End User (2024 and 2031)
  • Figure 13. Hospitals: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 14. Clinics: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 15. Others: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 16. Asia Pacific Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 17. China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 18. Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 19. India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 20. South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 21. Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 22. Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 23. Growth Strategies in the Therapeutic Vaccines Market